SIU Academy® - Official eLearning Portal of SIU (Société Internationale d'Urologie)

Learning Objectives
At the end of this programme, participants will be able to:
- Evaluate the benefits and risks of various treatment options across the treatment continuum in UC, RCC, and PCa.
- Analyze novel agents and treatment approaches for the evolving management of GU cancers based on emerging clinical data.
- Discuss strategies to identify and manage adverse events related to systemic treatment, including immunotherapy.
- Evaluate the role of imaging or genetic markers in guiding treatment decision-making.
- Discuss the importance of personalized medicine, based on costs and patient preference, while minimizing toxicity and maximizing efficacy.

Complete the session's evaluation form before November 13, 2023 to receive your CME certificate.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies